Literature DB >> 3753568

Histopathology of human lymph node tularemia caused by Francisella tularensis var palaearctica.

S Sutinen, H Syrjälä.   

Abstract

Histopathology of tularemia, caused by type-B strain, tuberculosis, and sarcoidosis were compared in lymph node biopsy specimens from ten patients with tularemia, 26 with tuberculosis, and 14 with sarcoidosis. In very early tularemia there were only reactive changes without necrosis. Abscess necrosis with or without epithelioid cell reaction was observed during the second week and caseous necrosis during the fourth week. Argyrophil fibers were absent from necrotic lesions in tularemia, but, often, also in tuberculosis. In most cases of tularemia and in half the cases of tuberculosis, the inflammatory process extended beyond the capsule of the lymph node. In some cases, tularemia could not be histologically differentiated from tuberculosis, but tularemia was always differentiated from sarcoidosis. Our series of lymph node tularemia seems to represent a milder disease than those cases published earlier. Tularemia should be considered in the differential diagnosis with tuberculosis, toxoplasmosis, and cat-scratch disease.

Entities:  

Mesh:

Year:  1986        PMID: 3753568

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

Review 1.  Tularemia: a rare cause of neck mass, evaluation of 33 patients.

Authors:  Sedat Cağlı; Alperen Vural; Onur Sönmez; Imdat Yüce; Ercihan Güney
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-08-04       Impact factor: 2.503

2.  Guillain-Barré syndrome and tularemia pleuritis with high adenosine deaminase activity in pleural fluid.

Authors:  H Syrjälä; P Koskela; P Kujala; V Myllylä
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

3.  Mac-1+ cells are the predominant subset in the early hepatic lesions of mice infected with Francisella tularensis.

Authors:  John W Rasmussen; Jeronimo Cello; Horacio Gil; Colin A Forestal; Martha B Furie; David G Thanassi; Jorge L Benach
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

4.  Characterization of the nucleotide sequence of the groE operon encoding heat shock proteins chaperone-60 and -10 of Francisella tularensis and determination of the T-cell response to the proteins in individuals vaccinated with F. tularensis.

Authors:  M Ericsson; I Golovliov; G Sandström; A Tärnvik; A Sjöstedt
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 5.  Tularemia presenting as tonsillopharyngitis and cervical lymphadenitis: a case report and review of the literature.

Authors:  Osman Kürşat Arikan; Can Koç; Onder Bozdoğan
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-01-10       Impact factor: 2.503

6.  Francisella tularensis induces extensive caspase-3 activation and apoptotic cell death in the tissues of infected mice.

Authors:  Jason R Wickstrum; Sirosh M Bokhari; Jeffrey L Fischer; David M Pinson; Hung-Wen Yeh; Rebecca T Horvat; Michael J Parmely
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

Review 7.  Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes.

Authors:  Caoimhe Egan; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2017-11-03       Impact factor: 3.464

8.  Peripheral blood leukocyte counts, erythrocyte sedimentation rate and C-reactive protein in tularemia caused by the type B strain of Francisella tularensis.

Authors:  H Syrjälä
Journal:  Infection       Date:  1986 Mar-Apr       Impact factor: 3.553

9.  Increased synthesis of DnaK, GroEL, and GroES homologs by Francisella tularensis LVS in response to heat and hydrogen peroxide.

Authors:  M Ericsson; A Tärnvik; K Kuoppa; G Sandström; A Sjöstedt
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Guillain-Barré syndrome and ulceroglandular tularemia.

Authors:  P Ylipalosaari; T I Ala-Kokko; H Tuominen; H Syrjälä
Journal:  Infection       Date:  2013-05-28       Impact factor: 7.455

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.